As shown in Table 2, the specific CDK7 inhibitors are predominantly assessed in patients with locally advanced or metastatic HR+/HER2- breast cancer, who exhibited failure in prior treatment with a CDK4/6 inhibitor in combination with hormonal therapy. This evidence concerns the gene ERBB2 and breast cancer.